VOYA Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$270M Buy
349,912
+55,863
+19% +$42.8M 0.28% 84
2025
Q4
$227M Buy
294,049
+166,513
+131% +$113M 0.22% 99
2025
Q3
$71.7M Sell
127,536
-45,270
-26% -$25.6M 0.07% 246
2025
Q2
$90.7M Sell
172,806
-16,438
-9% -$9.17M 0.09% 223
2025
Q1
$120M Buy
189,244
+35,410
+23% +$24.4M 0.13% 183
2024
Q4
$110M Sell
153,834
-33,446
-18% -$28.1M 0.11% 203
2024
Q3
$197M Buy
187,280
+115,077
+159% +$128M 0.2% 117
2024
Q2
$75.9M Sell
72,203
-10,624
-13% -$10.3M 0.07% 255
2024
Q1
$79.7M Buy
82,827
+6,798
+9% +$6.46M 0.08% 260
2023
Q4
$66.8M Sell
76,029
-1,278
-2% -$1.05M 0.07% 282
2023
Q3
$63.6M Sell
77,307
-2,793
-3% -$2.2M 0.07% 283
2023
Q2
$57.6M Sell
80,100
-2,781
-3% -$2.14M 0.06% 307
2023
Q1
$68.1M Sell
82,881
-11,902
-13% -$8.98M 0.07% 293
2022
Q4
$68.4M Buy
94,783
+4,650
+5% +$3.43M 0.08% 284
2022
Q3
$62.1M Buy
90,133
+38,926
+76% +$24.5M 0.07% 282
2022
Q2
$30.3M Buy
51,207
+1,260
+3% +$819K 0.08% 228
2022
Q1
$34.9M Sell
49,947
-1,026
-2% -$649K 0.07% 229
2021
Q4
$32.2M Buy
50,973
+8,407
+20% +$5.17M 0.06% 254
2021
Q3
$25.8M Sell
42,566
-1,088
-2% -$675K 0.05% 260
2021
Q2
$24.4M Sell
43,654
-8,654
-17% -$4.38M 0.05% 289
2021
Q1
$24.7M Sell
52,308
-3,933
-7% -$1.91M 0.05% 290
2020
Q4
$27.2M Buy
56,241
+8,216
+17% +$4.43M 0.06% 275
2020
Q3
$26.9M Buy
48,025
+2,543
+6% +$1.54M 0.06% 259
2020
Q2
$28.4M Buy
45,482
+11,398
+33% +$6.47M 0.07% 240
2020
Q1
$16.6M Sell
34,084
-238
-0.7% -$98.2K 0.04% 340
2019
Q4
$12.9M Buy
34,322
+3,843
+13% +$1.29M 0.03% 527
2019
Q3
$8.46M Buy
30,479
+329
+1% +$97.4K 0.02% 645
2019
Q2
$9.44M Buy
30,150
+751
+3% +$250K 0.02% 633
2019
Q1
$12.1M Buy
29,399
+582
+2% +$240K 0.03% 528
2018
Q4
$10.8M Buy
28,817
+109
+0.4% +$39.9K 0.03% 521
2018
Q3
$11.6M Sell
28,708
-568
-2% -$216K 0.02% 562
2018
Q2
$10.1M Buy
29,276
+835
+3% +$261K 0.02% 597
2018
Q1
$9.79M Sell
28,441
-258
-0.9% -$89.7K 0.02% 600
2017
Q4
$10.8M Sell
28,699
-1,110
-4% -$450K 0.02% 586
2017
Q3
$13.3M Sell
29,809
-425
-1% -$202K 0.03% 517
2017
Q2
$14.8M Buy
30,234
+844
+3% +$369K 0.03% 482
2017
Q1
$11.4M Buy
29,390
+117
+0.4% +$43.4K 0.03% 572
2016
Q4
$10.7M Buy
29,273
+202
+0.7% +$76.8K 0.03% 555
2016
Q3
$11.7K Sell
29,071
-645
-2% -$259K 0.02% 529
2016
Q2
$10.4M Sell
29,716
-460
-2% -$177K 0.03% 558
2016
Q1
$10.9M Sell
30,176
-375
-1% -$155K 0.03% 516
2015
Q4
$16.6M Sell
30,551
-600
-2% -$325K 0.04% 400
2015
Q3
$14.5M Buy
31,151
+1,128
+4% +$606K 0.04% 429
2015
Q2
$15.3M Buy
30,023
+325
+1% +$159K 0.04% 437
2015
Q1
$13.4M Sell
29,698
-167
-0.6% -$70.8K 0.03% 486
2014
Q4
$12.3M Sell
29,865
-1,214
-4% -$477K 0.03% 523
2014
Q3
$11.2M Sell
31,079
-3,299
-10% -$1.11M 0.03% 550
2014
Q2
$9.71M Buy
34,378
+857
+3% +$254K 0.02% 626
2014
Q1
$10.1M Buy
33,521
+257
+0.8% +$79.2K 0.02% 580
2013
Q4
$9.15M Sell
33,264
-4,993
-13% -$1.44M 0.02% 607
2013
Q3
$12M Sell
38,257
-81,090
-68% -$21.3M 0.03% 500
2013
Q2
$26.8M Buy
+119,347
New +$27.8M 0.07% 254

Other funds holding REGN

VOYA Investment Management's REGN Position: Q1 2026 in Review

VOYA Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, buying an estimated $42.8M and bringing the position to 349,912 shares worth $270M. The position accounts for 0.28% of the portfolio, ranked #84.

VOYA Investment Management first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • VOYA Investment Management held 349,912 shares of Regeneron Pharmaceuticals worth $270M as of Q1 2026.
  • VOYA Investment Management bought 55,863 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $42.8M.
  • Regeneron Pharmaceuticals made up 0.28% of VOYA Investment Management's portfolio in Q1 2026, its #84 holding.
  • VOYA Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.